Questions about the future regulation of combination products came to a head in 2015, and it's likely that significant changes will be put on the table in 2016.
From FDA, companies can expect a comprehensive proposal for a new approval pathway focused on combination products by the end of next year that could dovetail with efforts to reauthorize the device and drug user fee programs in 2017. Deputy Commissioner (and Commissioner-nominee) Robert Califf committed to as much at a recent congressional hearing